[go: up one dir, main page]

BR9713215A - Formulação de partìcula revestida - Google Patents

Formulação de partìcula revestida

Info

Publication number
BR9713215A
BR9713215A BR9713215-2A BR9713215A BR9713215A BR 9713215 A BR9713215 A BR 9713215A BR 9713215 A BR9713215 A BR 9713215A BR 9713215 A BR9713215 A BR 9713215A
Authority
BR
Brazil
Prior art keywords
coated particle
particle formulation
formulation
making
pharmaceutically acceptable
Prior art date
Application number
BR9713215-2A
Other languages
English (en)
Inventor
Tommy Clifford Morris
Hans Joerg Lange
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9713215A publication Critical patent/BR9713215A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Patente de Invenção:<B>"FORMULAçãO DE PARTìCULA REVESTIDA"<D>. A invenção fornece uma formulação oral sólida de olanzapina farmaceuticamente aceitável e um processo para fabricação de tal formulação.
BR9713215-2A 1996-09-24 1997-09-18 Formulação de partìcula revestida BR9713215A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2663396P 1996-09-24 1996-09-24
PCT/US1997/016547 WO1998013027A1 (en) 1996-09-24 1997-09-18 Coated particle formulation

Publications (1)

Publication Number Publication Date
BR9713215A true BR9713215A (pt) 2000-04-04

Family

ID=21832952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713215-2A BR9713215A (pt) 1996-09-24 1997-09-18 Formulação de partìcula revestida

Country Status (21)

Country Link
US (1) US20010020032A1 (pt)
EP (1) EP0830858A1 (pt)
JP (1) JP2001501207A (pt)
KR (1) KR20000048540A (pt)
CN (1) CN1230883A (pt)
AR (1) AR009802A1 (pt)
AU (1) AU719788B2 (pt)
BR (1) BR9713215A (pt)
CA (1) CA2266448A1 (pt)
CO (1) CO4910139A1 (pt)
CZ (1) CZ98899A3 (pt)
EA (1) EA001610B1 (pt)
HU (1) HUP9904065A3 (pt)
ID (1) ID21762A (pt)
IL (1) IL128845A0 (pt)
NO (1) NO991405L (pt)
PE (1) PE27899A1 (pt)
PL (1) PL332503A1 (pt)
TR (1) TR199900651T2 (pt)
WO (1) WO1998013027A1 (pt)
ZA (1) ZA978517B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
TWI275394B (en) * 2000-01-26 2007-03-11 Asahi Chemical Corp Mizoribin tablet improved with color tone change
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
CA2510319A1 (en) 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
KR101139744B1 (ko) * 2003-04-25 2012-04-26 미쓰비시 타나베 파마 코퍼레이션 알킬렌 디옥시벤젠 유도체 함유 경구 투여용 조성물
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
JP5820874B2 (ja) * 2010-04-30 2015-11-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
PH12021553056A1 (en) 2019-06-04 2023-09-11 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
CA2097016A1 (en) * 1992-05-29 1993-11-30 John Fairhurst Pharmaceutical compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine

Also Published As

Publication number Publication date
HUP9904065A2 (hu) 2000-04-28
CA2266448A1 (en) 1998-04-02
EP0830858A1 (en) 1998-03-25
IL128845A0 (en) 2000-01-31
TR199900651T2 (xx) 1999-07-21
ID21762A (id) 1999-07-22
HUP9904065A3 (en) 2001-10-29
NO991405D0 (no) 1999-03-23
AU4423097A (en) 1998-04-17
ZA978517B (en) 1999-03-23
WO1998013027A1 (en) 1998-04-02
AR009802A1 (es) 2000-05-03
JP2001501207A (ja) 2001-01-30
NO991405L (no) 1999-03-23
PL332503A1 (en) 1999-09-13
AU719788B2 (en) 2000-05-18
US20010020032A1 (en) 2001-09-06
CN1230883A (zh) 1999-10-06
EA001610B1 (ru) 2001-06-25
CO4910139A1 (es) 2000-04-24
KR20000048540A (ko) 2000-07-25
EA199900331A1 (ru) 2000-04-24
CZ98899A3 (cs) 1999-12-15
PE27899A1 (es) 1999-03-12

Similar Documents

Publication Publication Date Title
BR9713215A (pt) Formulação de partìcula revestida
HUP9900457A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ZA969001B (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
BR9611137A (pt) Composições e métodos para distribuição bucal de agentes farmacêuticos
MY113440A (en) Oral 2-methyl-thieno-benzodiazepine formulation
PT991653E (pt) Novos compostos
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP9901629A3 (en) Use of r(+)-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
HRP980163B1 (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates
EP1143956A3 (en) Compositions and methods for the treatment of anorectal disorders
BG104620A (en) Oral pharmaceutical extended release dosage form
HU9601161D0 (en) Use of retinoids in cosmetic compositions or for the manufacture of pharmaceutical compositions
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
AU6150498A (en) Methods and compositions for the inhibition of interleukin-12 production
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU2171297A (en) Pharmaceutical compositions and methods for the manufacture thereof
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
BR9712805A (pt) Processo para a preparação de compostos farmecêuticos
HUP9702465A3 (en) Epimers of (22rs)-n-(1,1,1,-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alfa-androst-1-ene-17beta-carboxamide, process for producing them and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1821 DE 29/11/2005.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NAS RPIS 1821 DE 29/11/2005, ITEM 8.6, E 1962 DE 12/08/2008, ITEM 8.11, POR TEREM SIDO INDEVIDOS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A, 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1986 DE 27/01/2009.